Pharmaceutical NanotechnologyDevelopment of novel sibutramine base-loaded solid dispersion with gelatin and HPMC: Physicochemical characterization and pharmacokinetics in beagle dogs
Introduction
Obesity is a chronic, multifactorial disorder that has reached epidemic proportions in most industrialized countries and is threatening to become a global epidemic (Popkin, 1998). The risks of morbidity and mortality increase with increasing body weight and waist circumference (an index of the visceral localization of fat). Obese patients have higher risks for coronary artery disease, hypertension, hyperlipidemia, diabetes mellitus, certain cancers, cerebrovascular accident, osteoarthritis, obstructive pulmonary disease, and sleep apnea (Rippe et al., 1998). Efforts to develop innovative anti-obesity drugs have intensified, and there have been calls for medically based outcome measures for obesity treatments that are more appropriate than those currently used (Clapham et al., 2001, Halpern and Mancini, 2003).
Sibutramine, an anti-obesity drug, is a potent inhibitor of the reuptake of noradrenaline and serotonin (Carek and Dickerson, 1999), and may stimulate thermogenesis by its activation of β3-adrenoceptors in brown adipose tissue (Connoley et al., 1999, McNeely and Goa, 1998). Sibutramine base has not been used in commercial products due to its poor water-solubility and instability. It has a solubility of about 0.01 mg/ml and a melting point of about 55 °C (Li et al., 2010). However, sibutramine hydrochloride monohydrate, a salt form, has been used in a commercial product (Reductil®) because of its improved solubility and stability (McNeely and Goa, 1998). It has a solubility of about 3 mg/ml at pH 5.2 and a melting point of about 190 °C (Fang et al., 1999). Recently, considerable attention has been focused on the improvement of drug solubility by synthesizing different salt forms. Sibutramine mesylate (Kim et al., 2005) and sibutramine tartrate (HPC, 2006) have been synthesized, and showed an increase in solubility to 2500 and 500 mg/ml at pH 5.2, respectively. However, in order to use these new synthesized materials as commercial products, clinical tests must be carried out. Another oral formulation of sibutramine base, a solid dispersion prepared with poloxamer, was developed but showed little improvement in solubility (Li et al., 2010, Sheen et al., 1995).
Thus, in this study, in order to develop a novel sibutramine base-loaded solid dispersion with enhanced solubility and bioavailability, various solid dispersion systems were prepared using a spray drying technique with hydrophilic polymers such as gelatin, HPMC and citric acid. Their solubility, thermal characteristics and crystallinity were investigated. The dissolution and pharmacokinetics of the sibutramine base-loaded solid dispersion were compared with a sibutramine hydrochloride monohydrate-loaded commercial product.
Section snippets
Materials
Sibutramine base, HPMC 2910 (hydroxypropylmethylcellulose 2910) and gelatin were obtained from Cipla Co. (India), Shin-Etsu Co. (Tokyo, Japan) and Sammi Co. (Anyang, South Korea), respectively. Citric acid was provided by Yung-Jin Pharm. Co. (Anyang, South Korea) and was of USP grade. The commercial product (Reductil®; in capsule form) was purchased from Abbott Korea Co. (Seoul, South Korea). All other chemicals were of reagent grade and were used without further purification.
Animals
All animal care
Results and discussion
In this study, the solid dispersion system was prepared using a spray drying technique with hydrophilic polymers in order to improve the solubility of the poorly water-soluble sibutramine base. Hydrophilic polymers such as gelatin and HPMC were dissolved in 30% ethanol and the poorly water-soluble drug was suspended or dissolved in these solutions. The resulting solutions were spray-dried so that the sibutramine base formed a solid dispersion together with the hydrophilic polymers (Joe et al.,
Conclusion
In conclusion, the sibutramine base-loaded solid dispersion composed of sibutramine base/gelatin/HPMC/citric acid at the weight ratio of 1/0.8/0.2/0.5 gave a solubility of 5.03 ± 0.24 mg/ml. Furthermore, it showed similar dissolution to the sibutramine hydrochloride monohydrate-loaded commercial product and was bioequivalent to the commercial product in beagle dogs. Thus, the sibutramine base-loaded solid dispersion prepared with gelatin, HPMC and citric acid is a promising candidate for improving
Acknowledgements
This work was supported by Mid-career Researcher Program through NRF grant funded by the MEST (No. 2010-0000363) and financially supported by the Ministry of Science and Technology (M10414030001-05N1403-00140) in South Korea.
References (28)
- et al.
Analysis of enantiomers of sibutramine and its metabolites in rat plasma by liquid chromatography–mass spectrometry using a chiral stationary-phase column
J. Pharmaceut. Biomed.
(2009) - et al.
Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques
Int. J. Pharm.
(1995) - et al.
Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen
J. Control. Rel.
(2005) - et al.
Anti-obesity drugs: a critical review of current therapies and future opportunities
Pharmacol. Ther.
(2001) - et al.
Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus
Int. J. Pharm.
(2010) - et al.
Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique
Int. J. Pharm.
(1999) - et al.
Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray drying technique
Int. J. Pharm.
(2008) - et al.
The influence of additives on the cloud point, disintegration and dissolution of hydroxypropylmethylcellulose gels and matrix tablets
Int. J. Pharm.
(1990) - et al.
Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188
Int. J. Pharm.
(2007) - et al.
Obesity as a chronic disease: modern medical and lifestyle management
J. Am. Diet. Assoc.
(1998)